Mots C.
F💡 Explain this simply
Mots C is a research compound in the mitochondrial & longevity peptides.
It draws interest for mitochondrial & longevity peptides.
F-tier evidence: human evidence is limited; most support is preclinical.
General anti-aging / longevity; Human injury recovery; Muscle growth or fat loss claims.
Interesting on paper, but not a clinically proven option. The internet narrative is stronger than the human evidence.
Before you decide, compare Mots C with Ss 31, Humanin, Epitalon. See all →
Mots C is a research compound in the mitochondrial & longevity peptides.
Mitochondria-derived peptides studied in metabolism and stress responses.
It draws interest for mitochondrial & longevity peptides.
F-tier evidence: human evidence is limited; most support is preclinical.
A mitochondrial-derived peptide studied for metabolism and exercise biology — predominantly preclinical (cell and animal models). No approved therapeutic use and essentially no human outcome trials; among the more hype-prone longevity peptides.
Verified citations resolve to PubMed / FDA. See how we score.
Mots C: the research file
What it is
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome, first described around 2015. It belongs to a small family of "mitochondrial-derived peptides" that appear to act as metabolic signaling molecules. It is an investigational research compound, not an approved drug, and is frequently grouped with longevity peptides where hype tends to outrun the evidence.
How it works
In preclinical models MOTS-c is described as a stress-responsive signaling peptide: it has been reported to activate the AMPK energy-sensing pathway and to influence folate and methionine (one-carbon) metabolism, and under metabolic stress it can translocate to the cell nucleus where it is proposed to help regulate adaptive, antioxidant gene expression. These mechanisms are largely characterized in cell and animal systems; how faithfully they translate to a clinical effect in people is not established.
What the evidence shows
The evidence base is predominantly preclinical. The foundational study (Lee et al., Cell Metabolism, 2015) reported that MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in mice, and later work has linked it to exercise physiology and measured circulating levels in humans as a biomarker. However, there are no controlled human trials demonstrating that administering MOTS-c produces a meaningful clinical benefit. The gap between the animal/mechanistic data and proven human outcomes is large and should not be glossed over.
Safety considerations
Human safety is essentially uncharacterized. There are no published human toxicology, long-term, or drug-interaction data for administered MOTS-c. As an injectable compound sold research-use-only, the purity, identity, and sterility of non-pharmaceutical material are additional unknowns on top of the absent clinical safety package. It should be regarded as an experimental compound of unknown human risk.
Regulatory status
MOTS-c is not approved by the FDA (or any major regulator) for any indication and is not a recognized dietary supplement; it is an investigational, research-use-only compound with no registered human therapeutic trials.
- A mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region, described around 2015
- Proposed to act through AMPK and one-carbon (folate/methionine) metabolism in preclinical models
- The foundational evidence is a 2015 mouse study showing improved metabolic homeostasis and reduced insulin resistance
- Studied in humans mainly as an exercise-responsive biomarker, not in controlled treatment trials
- No published human safety, pharmacokinetic, or efficacy data for administered MOTS-c
- Not FDA-approved; sold research-use-only and among the more hype-prone longevity peptides
- [1]Lee C et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance — Cell Metab, 2015 (PMID 25738459)
- [2]Mitochondrial-derived peptides (MOTS-c) and exercise/metabolism — peer-reviewed literature — PubMed / NCBI
Currently sits at Animal — Findings come mainly from animal models, not people.
Jargon, decoded: · ·
Areas this compound is studied or discussed for — not guaranteed effects.
- MOTS-c is a mitochondrial-derived peptide — a short peptide encoded within the mitochondrial 12S rRNA gene.
- It is studied as a regulator of metabolic homeostasis and insulin sensitivity, sometimes described as an “exercise-mimetic” signal in animal models.
- Evidence is mainly preclinical; human data is minimal.
- Not FDA-approved; research-only.
- “Reverses aging / boosts metabolism” claims rest on animal work, not human outcomes.
Marketing claim vs what the data actually shows. Tap a row for detail.
Verdicts describe the state of the evidence, not invented study results. Open References for the underlying citations.
Stack fit
Decision clarity: UnknownNot enough indexed evidence to assess.
Stack verdict: Interesting on paper, but not a clinically proven option. The internet narrative is stronger than the human evidence.
Mots C is not established for:
Tier ranking
A weighted evidence score of 30/100 places mots-c in F tier — based on published evidence, not popularity.
Weighted evidence score 30/100
Why not D: held back by human evidence, safety clarity, regulatory clarity, practical relevance.
What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.
What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.
- Mots C is not FDA-approved for human use; it is discussed in a research context.
- It belongs to the Mitochondrial & longevity peptides class.
- Its principal mechanism is characterized in the literature.
- Whether observed effects reliably translate to humans at large.
- Long-term safety in healthy users, and full drug-interaction risk.
- Optimal studied parameters outside any approved indication.
- Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
- Quality and purity of material from non-pharmaceutical sources.
This is not medical advice. These are areas where professional guidance and better evidence matter most.
See it next to its closest alternatives.
Full brief
A deeper, chapter-by-chapter research briefing. Tap any chapter to expand.
- What it is
- The Mitochondrial peptide signalling mechanism
- The preclinical evidence lane
- Why Preliminary, and not higher or lower
- Proven lane vs speculative lane
- What people report
- Regulatory status
- What changed recently
01What it is
Simple takeaway: Mots C is a research compound in the mitochondrial & longevity peptides.
Mitochondria-derived and longevity-associated research peptides. Among the most hype-prone and least clinically validated groups. It is not approved for human use; it is discussed here in a research context only.
02The Mitochondrial peptide signalling mechanism
Simple takeaway: Mitochondria-derived peptides studied in metabolism and stress responses.
Mitochondria-derived peptides such as MOTS-c and humanin, and mitochondrially-targeted peptides such as SS-31, are studied for roles in mitochondrial function, metabolism, and cellular stress responses — predominantly in preclinical settings.
03The preclinical evidence lane
Simple takeaway: Support is mainly preclinical; 0 registered trials and 0 sources indexed.
The most defensible evidence comes from animal and mechanistic models. Human clinical evidence is limited.
04Why Preliminary, and not higher or lower
Simple takeaway: Composite maturity 1.8/5.
What holds it back: human evidence, safety clarity, regulatory clarity, practical relevance. What supports its placement: its overall evidence profile. Stronger human trials, clearer long-term safety data, and regulatory progress would move it up; a safety signal or failure to replicate would move it down.
05Proven lane vs speculative lane
Simple takeaway: The research interest is real; most popular claims remain speculative.
What's supported is the preclinical/mechanistic research. What's speculative is the broad human benefit frequently claimed online, which the indexed human evidence does not establish.
06What people report
Simple takeaway: Community reports are not clinical evidence.
Online reports can surface expectation patterns and possible safety signals, but they are shaped by placebo effects, selection bias, confounders, and uncertain product quality and sourcing. We don't treat anecdotes as proof and we don't publish dosing or protocols.
07Regulatory status
Simple takeaway: Research-use-only
Not approved by the FDA for human use; studied in research contexts. Regulatory status can change and differs by country; several peptides are also prohibited in sport (WADA). Verify current status before relying on it.
08What changed recently
Simple takeaway: No major evidence-changing update was identified in this review window.
The current profile reflects the existing body of indexed evidence. Material changes — new trials, approvals, or safety findings — are noted here when an editor logs them.
How the community sees this vs the evidence.
Evidence tier is F. Do you agree?
Community votes reflect user perception, not scientific proof — the evidence tier comes from our Research Maturity Index. Aggregate community sentiment will appear here once enough votes are collected.
Aggregate community sentiment will appear here once enough votes are in — we don't show invented numbers.
Get notified when new studies, safety updates, regulatory changes, or the tier ranking change.
FAQs
Is Mots C FDA-approved?
No. Mots C is not FDA-approved for the uses commonly discussed online. Not approved by the FDA for human use; studied in research contexts.
What is Mots C studied for?
Mots C is studied mainly for longevity. Mitochondria-derived and longevity-associated research peptides. Among the most hype-prone and least clinically validated groups.
What does the research say about Mots C?
Mostly animal evidence. Human data is limited; most support comes from preclinical research.
Is Mots C safe?
Long-term human safety is not well established for Mots C. Quality and purity from non-pharmaceutical sources is an added risk.
🧮 Reconstitution calculator (educational)
Educational reconstitution math from your own values — not medical advice or a dose recommendation. Open the full calculator →
Each unit on a 100u · 1.0 mL syringe ≈ 25 mcg of this solution.
Show the math
More water → lower concentration → more units for the same amount.
Get the vial, water, target, and 10-unit draw sent to your inbox so it's easy to reference — and follow when the evidence changes. Free, no account.
Research reference only. Not medical advice, treatment instructions, or a purchase recommendation. Consult a licensed professional.